Patents Assigned to Allergan
  • Synthetic bile acid compositions and methods
    Patent number: 11026955
    Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: June 8, 2021
    Assignee: Allergan Sales, LLC
    Inventors: Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood
  • Heavy chain only antibodies to PDGF
    Patent number: 11028163
    Abstract: Disclosed herein are monospecific HCAb antibodies with antigen-binding specificity to PDGF and bispecific antibodies with antigen-binding specificities to PDGF-2 and VEGF or to PDGF and ANG-2.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: June 8, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Yanbin Liang, Daniel W. Gil
  • Hyaluronic acid-based gels including lidocaine
    Patent number: 11020512
    Abstract: Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: June 1, 2021
    Assignee: ALLERGAN INDUSTRIE, SAS
    Inventor: Pierre F. Lebreton
  • Preparation of bile acids and intermediates thereof
    Patent number: 11008363
    Abstract: Synthetic methods for preparing deoxycholic acid and intermediates thereof are provided.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: May 18, 2021
    Assignee: Allergan Sales, LLC
    Inventors: Achampeta Rathan Prasad, Roy A. Swaringen, Jr., John Gregory Reid, Robert M. Moriarty, Akhila Kumar Sahoo
  • Opioid receptor modulator dosage formulations
    Patent number: 11007179
    Abstract: Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-4,5-dihydro-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
    Type: Grant
    Filed: October 8, 2020
    Date of Patent: May 18, 2021
    Assignee: Allergan Holdings Unlimited Company
    Inventors: Tim Costello, Jens Jozef Ceulemans, Eugeen Maria Jozef Jans, Philip Erna H. Heyns
  • Dermal filler compositions including antioxidants
    Patent number: 11000626
    Abstract: Provided are injectable, hyaluronic acid-based dermal filler compositions including conjugated vitamin C derivatives. The compositions provide for extended release of active vitamin C into tissue, promoting collagenesis and other benefits to skin.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: May 11, 2021
    Assignee: ALLERGAN INDUSTRIE, SAS
    Inventors: Futian Liu, Xiaojie Yu, Jessamine P. Winer-Jones, Nicholas J. Manesis, Hengli Liu, Gabriel Njikang, Athene Wan Chie Chan
  • Dermal filler compositions for fine line treatment
    Patent number: 10994049
    Abstract: The present invention provides highly injectable, long-lasting hyaluronic acid-based hydrogel dermal filler compositions which are particularly advantageous for correction of fine lines in the face.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: May 4, 2021
    Assignee: ALLERGAN INDUSTRIE, SAS
    Inventors: Gabriel N. Njikang, Xiaojie Yu, Futian Liu, Sumit Paliwal, Nicholas J. Manesis
  • Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
    Patent number: 10993931
    Abstract: The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: May 4, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Richard L. Beard, Tien T. Duong, John E. Donello, Veena Viswanath, Michael E. Garst
  • Digestive enzyme composition suitable for enteral administration
    Patent number: 10993996
    Abstract: The present invention is directed to a digestive enzyme composition comprising an enterically coated digestive enzyme product, administrable nutritional medium, and a pharmaceutically acceptable low viscosity oily ingredient. The process for the preparation of the digestive enzyme composition comprises adding an enterically coated digestive enzyme product to a administrable nutritional medium and pharmaceutically acceptable low viscosity oily ingredient. The invention further provides a method for treating a patient suffering from exocrine pancreatic insufficiency related condition comprising administering to the patient a therapeutically effective dose of the digestive enzyme composition by means of a feeding tube.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: May 4, 2021
    Assignee: Allergan Pharmaceuticals International Limited
    Inventors: Devrim Eren, Ruth Thieroff-Ekerdt, Luigi Boltri, Vincenza Pironti, Letizia Ubliglia
  • Dissolvable microneedles for skin treatment
    Patent number: 10987503
    Abstract: A skin treatment can include applying a microneedle device to a region of the skin so that microneedles of the device penetrate the stratum corneum. The arrangement of microneedles can have first microneedles with a first length and second microneedles with a second length, different from the first length. The first and second microneedles can be formed from a mixture of a polymeric material and an active agent beneficial to skin. After the device is applied to the skin, the first and second microneedles can be released below the skin surface, followed by dissolution of the first and second microneedles.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: April 27, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Justin J. Schwab, Michael Augarten, Zachary Dominguez, Ethan Franklin, Edwin J. Kayda, Jason Metzner
  • Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
    Patent number: 10988474
    Abstract: The present invention provides a compound, that is a 1-({halo-2-[(2-hydrocarbyl or substituted hydrocarbyl)oxy]phenyl}methyl)-(fused bicyclic nitrogen heteroaryl) carboxylic acid or an ester or sulfonamide thereof. The compound may be represented by the following formula Wherein R1, R2, R3, R4 A, X, W, Z and Y are as defined in the specification. The compounds may be administered to treat DP, FP, EP1, TP and/or EP4 receptor-mediated diseases or conditions.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: April 27, 2021
    Assignee: ALLERGAN, INC.
    Inventors: William R. Carling, Jose L. Martos, Jussi J. Kangasmetsa, Jenny W. Wang, David F. Woodward
  • Methods for the purification of deoxycholic acid
    Patent number: 10981946
    Abstract: Synthetic methods for preparing deoxycholic acid and intermediates thereof, high purity synthetic deoxycholic acid, compositions and methods of use are provided. Also, provided are processes for the synthesis of 12-keto or 12-?-hydroxysteroids from ?-9,11-ene, 11-keto or 11-hydroxy-?-steroids. This invention is also directed to novel compounds prepared during the synthesis. This invention is also directed to the synthesis of deoxycholic acid starting from hydrocortisone.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: April 20, 2021
    Assignee: Allergan Sales, LLC
    Inventors: Robert M. Moriarty, Achampeta Rathan Prasad, John Gregory Reid, Roy A. Swaringen, Jr.
  • Non-protein clostridial toxin compositions
    Patent number: 10973890
    Abstract: Pharmaceutical compositions that stabilize a Clostridial toxin active ingredient are described. The compositions can be liquid or solid compositions, and comprise a surfactant and an antioxidant. In some embodiments, the compositions comprise a surfactant selected from a poloxamer and a polysorbate; an antioxidant selected from methionine, N-acetyl cysteine, ethylenediaminetetraacetic acid and combinations thereof, and, optionally, a tonicity agent and/or a lyoprotector selected from, for example, trehalose, sucrose.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: April 13, 2021
    Assignee: Allergan, Inc.
    Inventors: Maurice Abiad, Bhas Dani, Evgenyi Shalaev
  • Formulations of deoxycholic acid and salts thereof
    Patent number: 10946030
    Abstract: The present application is directed to an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid, wherein the composition is maintained at a pH from about 8.1 to about 8.5 such that the composition is stabilized against precipitation. Also disclosed herein, are methods for stabilizing an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid against precipitation, said method comprising maintaining pH of the solution from about 8.1 to about 8.5.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: March 16, 2021
    Assignee: Allergan Sales, LLC
    Inventors: Robert Emil Hodge, Jeffrey Douglas Webster, Robert M. Moriarty
  • Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin
    Patent number: 10912823
    Abstract: Methods for treating melanin-related afflictions of the skin, such as hyperpigmentation, are provided. The methods comprise administering a composition comprising BoNT/DC.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: February 9, 2021
    Assignee: Allergan, Inc.
    Inventors: Birgitte P.S. Jacky, Shiazah Z. Malik, Joanne Wang, Yi Liu, Amy Brideau-Andersen, Lance E. Steward, Linh Q. Le, Edward C. Hsai
  • Androgen composition for treating an ophthalmic condition
    Patent number: 10905696
    Abstract: The disclosure provides compositions for treating an ocular condition. The composition comprises a physiologically effective amount of an androgen, wherein the composition is suitable for topical administration to an eye. The disclosure further provides methods for treating an ocular condition with the disclosed compositions.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: February 2, 2021
    Assignee: ALLERGAN, INC.
    Inventors: John T. Trogden, Adnan K. Salameh, Chetan P. Pujara, Anuradha V. Gore, Jaya Giyanani
  • Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
    Patent number: 10905797
    Abstract: Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and optionally including proteins. In one aspect, hyaluronic acid-based compositions described herein include zero-length cross-linked moieties and optionally at least one active agent. The present hyaluronic acid-based compositions have enhanced flow characteristics, hardness, and persistence compared to known hyaluronic acid-based compositions. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: February 2, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Karina Heredia Guillen, Ahmet Tezel
  • Bioerodible matrix for tissue involvement
    Patent number: 10898607
    Abstract: Disclosed herein are polyurethane polymer matrices with a porosity of from about 20 microns to about 90 microns that are useful in promoting closure and protection of incision sites; supporting the lower pole position of breast implants; and providing a partial or complete covering of breast implants to provide a beneficial interface with host tissue and to reduce the potential for malpositioning or capsular contracture. The disclosed matrices can be seeded with mammalian cells.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: January 26, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Dennis E. Van Epps, Thomas E. Powell
  • Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
    Patent number: 10899780
    Abstract: The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: January 26, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Richard L. Beard, John E. Donello, Veena Viswanath
  • Immuno-based retargeted endopeptidase activity assays
    Patent number: 10900967
    Abstract: The present specification discloses a retargeted endopeptidase pharmaceutical wherein the activity has been determined by the methods disclosed.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: January 26, 2021
    Assignee: Allergan, Inc.
    Inventors: Joanne Wang, Hong Zhu, Dianne D. Hodges, Ester Fernandez-Salas